Abstract:BACKGROUND: The WHO Comprehensive Mental Health Action Plan 2013-2030 encourages routine collection and reporting of a set of essential mental health indicators, including the availability of psychotropic medicines. The global monitoring of country-level psychotropic medicine consumption trends can provide information on the extent of the availability of psychotropic medicines. The primary objective of this study was to investigate global trends in psychotropic medicines consumption from 2008 to 2019 across 65 countries and regions according to country income level and geographical region.METHODS: In this longitudinal trends study, we used pharmaceutical sales data from the IQVIA-Multinational Integrated Data Analysis System (IQVIA-MIDAS). We analysed monthly sales data of psychotropic medicines between Jan 1, 2008, and Dec 31, 2019. Total psychotropic medicine consumption included sales of antidepressants, antipsychotics, tranquilisers, sedatives or hypnotics, and mood stabilisers. Population estimates of each country or region (eight lower-middle-income countries, 19 upper-middle-income countries, and 38 high-income countries) were based on the UN World Population Prospects 2019 report. Average annual sales trends of psychotropic medicines, expressed as defined daily dose (DDD) per 1000 inhabitants per day, were estimated using a random-effects model adjusted for income level and region. Relative changes in the annual consumption of psychotropic medicines by income, expressed as DDD per 1000 inhabitants per day, were assessed as percentage change for each medicine class.FINDINGS: Psychotropic medicine sales increased from 28·54 DDD per 1000 inhabitants per day in 2008 to 34·77 DDD per 1000 inhabitants per day in 2019, corresponding to a 4·08% (95% CI 2·96-5·21) relative average increase annually. The absolute annual increase was greater in high-income countries (3·31 DDD per 1000 inhabitants per day, 95% CI 3·01-3·61) compared with upper-middle-income countries (1·94 DDD per 1000 inhabitants per day, 1·45-2·44) and low-middle-income countries (0·88 DDD per 1000 inhabitants per day, 0·62-1·13; p<0·0001). The relative average annual increase in psychotropic medicine sales from 2008 to 2019 was greater in upper-middle-income countries (7·88%, 95% CI 6·99-8·77) than in lower-middle-income countries (2·90%, 2·40-3·39) and high-income countries (1·02%, 0·80-1·24). In 2019, the regional consumption of psychotropic medicines varied greatly, with the highest sales of all psychotropic medicine classes reported in northern America (167·54 DDD per 1000 inhabitants per day) and lowest sales reported in Asia (5·59 DDD per 1000 inhabitants per day). 17 countries had very low consumption of psychotropic medicines in 2019, including high-income countries and countries with a high prevalence of mental disorders.INTERPRETATION: The consumption of psychotropic medicines has increased over a 12-year period, and although the absolute growth rate was highest in high-income countries, the relative growth is highest in middle-income countries and especially upper-middle-income countries. Disparities in psychotropic medicine consumption of countries can only partly be explained by geographical location and income. Greater efforts are needed to increase the availability of psychotropic medicines in countries with very low consumption, which is probably due to financial or cultural reasons as well as scarcity of trained health-care professionals to prescribe psychotropic medicines.FUNDING: None.

The usage of anticholinergic medications in a low- and middle-income country: a longitudinal comparison of 2013–15 and 2020–22 datasets

Anticholinergic Use Trends in 14,013 Patients with Schizophrenia from Three National Surveys on the Use of Psychotropic Medications in China (2002–2012)

Use of Anticholinergic Drugs in Patients with Schizophrenia in Asia from 2001 to 2009

Common Use of Anticholinergic Medications in Older Patients with Schizophrenia: Findings of the Research on Asian Psychotropic Prescription Pattern (REAP) Study, 2001–2009

Adjunctive Antidepressant Use In Schizophrenia In China: A National Survey (2002-2012)

Antipsychotic Medications in Major Depression and the Association with Treatment Satisfaction and Quality of Life: Findings of Three National Surveys on Use of Psychotropics in China Between 2002 and 2012

Change in Antibiotic Use in Secondary and Tertiary Hospitals Nationwide after a National Antimicrobial Stewardship Campaign Was Launched in China, 2011-2016: an Observational Study.

Psychotropic medicine consumption in 65 countries and regions, 2008–19: a longitudinal study

Trends in the utilization of psychotropic medications in China from 2018 to 2021

Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: Comparison of REAP-2001 and REAP-2004 studies: Prescribing antipsychotics in REAP study

Changes In Use Of Antidiabetic Medications Following Price Regulations In China (1999-2009)

Prescribing Patterns of Low Doses of Antipsychotic Medications in Older Asian Patients with Schizophrenia, 2001–2009

Does self-medication reduce medical expenditure among the middle-aged and elderly population? A four-wave longitudinal study in China

Trends in Psychotropic Medication Prescriptions in Urban China From 2013 to 2017: National Population-Based Study

Prevalence of strong anticholinergic use in residents with and without cognitive impairment and frailty: Analysis from 106 nursing homes in 12 Asia-Pacific and European countries

Changes of the Types and Daily Costs of Topical Antiglaucoma Medications from 2006 to 2021 in China

Trends and Patterns of Antibiotic Consumption in Shanghai Municipality, China: A 6 Year Surveillance with Sales Records, 2009-14

Low Doses of Antipsychotic Drugs for Hospitalized Schizophrenia Patients in East Asia: 2004 Vs. 2001.

Secular Trend Analysis of Antibiotic Consumption in China’s Hospitals 2011-2018, a Retrospective Analysis of Sales Data

Author Response for "time Trends and Regional Variation in Utilization of Antidiabetic Medicines in China, 2015–2022"

Measuring Temporal Trends and Patterns of Inpatient Antibiotic Use in Northwest China's Hospitals: Data from the Center for Antibacterial Surveillance, 2012-2022